283 related articles for article (PubMed ID: 15254918)
1. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials.
Whitehead A; Perdomo C; Pratt RD; Birks J; Wilcock GK; Evans JG
Int J Geriatr Psychiatry; 2004 Jul; 19(7):624-33. PubMed ID: 15254918
[TBL] [Abstract][Full Text] [Related]
2. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
Rogers SL; Doody RS; Mohs RC; Friedhoff LT
Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
[TBL] [Abstract][Full Text] [Related]
3. Donepezil for dementia due to Alzheimer's disease.
Birks JS; Harvey RJ
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.
Doody RS; Corey-Bloom J; Zhang R; Li H; Ieni J; Schindler R
Drugs Aging; 2008; 25(2):163-74. PubMed ID: 18257603
[TBL] [Abstract][Full Text] [Related]
5. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
Rogers SL; Farlow MR; Doody RS; Mohs R; Friedhoff LT
Neurology; 1998 Jan; 50(1):136-45. PubMed ID: 9443470
[TBL] [Abstract][Full Text] [Related]
6. Donepezil for mild and moderate Alzheimer's disease.
Birks JS; Melzer D; Beppu H
Cochrane Database Syst Rev; 2000; (4):CD001190. PubMed ID: 11034704
[TBL] [Abstract][Full Text] [Related]
7. Donepezil for dementia due to Alzheimer's disease.
Birks J; Harvey RJ
Cochrane Database Syst Rev; 2006 Jan; (1):CD001190. PubMed ID: 16437430
[TBL] [Abstract][Full Text] [Related]
8. Donepezil for dementia due to Alzheimer's disease.
Birks JS; Harvey R
Cochrane Database Syst Rev; 2003; (3):CD001190. PubMed ID: 12917900
[TBL] [Abstract][Full Text] [Related]
9. Donepezil for mild and moderate Alzheimer's disease.
Birks J S; Melzer D
Cochrane Database Syst Rev; 2000; (2):CD001190. PubMed ID: 10796620
[TBL] [Abstract][Full Text] [Related]
10. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.
Rogers SL
Dement Geriatr Cogn Disord; 1998; 9 Suppl 3():29-42. PubMed ID: 9853200
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
Farlow MR; Salloway S; Tariot PN; Yardley J; Moline ML; Wang Q; Brand-Schieber E; Zou H; Hsu T; Satlin A
Clin Ther; 2010 Jul; 32(7):1234-51. PubMed ID: 20678673
[TBL] [Abstract][Full Text] [Related]
12. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
13. The effects of donepezil in Alzheimer's disease - results from a multinational trial.
Burns A; Rossor M; Hecker J; Gauthier S; Petit H; Möller HJ; Rogers SL; Friedhoff LT
Dement Geriatr Cogn Disord; 1999; 10(3):237-44. PubMed ID: 10325453
[TBL] [Abstract][Full Text] [Related]
14. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL
JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278
[TBL] [Abstract][Full Text] [Related]
15. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
[TBL] [Abstract][Full Text] [Related]
16. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
17. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study.
Maher-Edwards G; Dixon R; Hunter J; Gold M; Hopton G; Jacobs G; Hunter J; Williams P
Int J Geriatr Psychiatry; 2011 May; 26(5):536-44. PubMed ID: 20872778
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.
Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T
Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study.
Boada-Rovira M; Brodaty H; Cras P; Baloyannis S; Emre M; Zhang R; Bahra R;
Drugs Aging; 2004; 21(1):43-53. PubMed ID: 14715043
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study.
Rogers SL; Friedhoff LT
Eur Neuropsychopharmacol; 1998 Feb; 8(1):67-75. PubMed ID: 9452942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
